United States - English - NLM (National Library of Medicine)

bausch & lomb incorporated - benoxinate hydrochloride (unii: 0ve4u49k15) (benoxinate - unii:axq0jym303), fluorescein sodium (unii: 93x55pe38x) (fluorescein - unii:tpy09g7xir) - benoxinate hydrochloride 4 mg in 1 ml - for procedures requiring a disclosing agent in combination with a topical ophthalmic anesthetic agent such as tonometry, gonioscopy, removal of corneal foreign bodies and other short corneal or conjunctival procedures. known hypersensitivity to any component of this product. prolonged use of a topical ocular anesthetic is not recommended. it may produce permanent corneal opacification with accompanying visual loss.

United States - English - NLM (National Library of Medicine)

altaire pharmaceuticals inc. - benoxinate hydrochloride (unii: 0ve4u49k15) (benoxinate - unii:axq0jym303), fluorescein sodium (unii: 93x55pe38x) (fluorescein - unii:tpy09g7xir) - benoxinate hydrochloride 4 mg in 1 ml - altafluor benox (fluorescein sodium and benoxinate hydrochloride ophthalmic solution) 0.25%/0.4% is indicated for ophthalmic procedures requiring a disclosing agent in combination with a topical ophthalmic anesthetic agent. altafluor benox is contraindicated in patients with known hypersensitivity to any component of this product. risk summary   there are no available data on the use of altafluor benox in pregnant women to inform any drug associated risk. adequate animal reproduction studies have not been conducted with fluorescein sodium and/or benoxinate hydrochloride. altafluor benox should be given to a pregnant woman only if clearly needed. risk summary    there are no data on the presence of fluorescein sodium or benoxinate hydrochloride in human milk after ocular administration of altafluor benox, the effects on the breastfed infant, or the effects on milk production. the developmental and health benefits of breastfeeding should be considered, along with the mother’s clinical need for altafluor benox a

United States - English - NLM (National Library of Medicine)

bausch & lomb incorporated - fluorescein sodium (unii: 93x55pe38x) (fluorescein - unii:tpy09g7xir), benoxinate hydrochloride (unii: 0ve4u49k15) (benoxinate - unii:axq0jym303) - fluorescein sodium and benoxinate hydrochloride ophthalmic solution, 0.3%/0.4% is indicated for ophthalmic procedures in adult and pediatric patients requiring a disclosing agent in combination with a topical ophthalmic anesthetic agent. fluorescein sodium and benoxinate hydrochloride ophthalmic solution, 0.3%/0.4% is contraindicated in patients with known hypersensitivity to any component of this product. risk summary there are no available data on the use of fluorescein sodium and benoxinate hydrochloride ophthalmic solution, 0.3%/0.4% in pregnant women to inform any drug associated risk. adequate animal reproduction studies have not been conducted with fluorescein sodium and/or benoxinate hydrochloride. fluorescein sodium and benoxinate hydrochloride ophthalmic solution, 0.3%/0.4% should be given to a pregnant woman only if clearly needed. risk summary there are no data on the presence of fluorescein sodium or benoxinate hydrochloride in human milk after ocular administration of fluorescein sodium and beno

United States - English - NLM (National Library of Medicine)

oceanside pharmaceuticals - fluorescein sodium (unii: 93x55pe38x) (fluorescein - unii:tpy09g7xir), benoxinate hydrochloride (unii: 0ve4u49k15) (benoxinate - unii:axq0jym303) - fluorescein sodium and benoxinate hydrochloride ophthalmic solution, 0.3%/0.4% is indicated for ophthalmic procedures in adult and pediatric patients requiring a disclosing agent in combination with a topical ophthalmic anesthetic agent. fluorescein sodium and benoxinate hydrochloride ophthalmic solution, 0.3%/0.4% is contraindicated in patients with known hypersensitivity to any component of this product. risk summary there are no available data on the use of fluorescein sodium and benoxinate hydrochloride ophthalmic solution, 0.3%/0.4% in pregnant women to inform any drug associated risk. adequate animal reproduction studies have not been conducted with fluorescein sodium and/or benoxinate hydrochloride. fluorescein sodium and benoxinate hydrochloride ophthalmic solution, 0.3%/0.4% should be given to a pregnant woman only if clearly needed. risk summary there are no data on the presence of fluorescein sodium or benoxinate hydrochloride in human milk after ocular administration of fluorescein sodium and beno

United States - English - NLM (National Library of Medicine)

bausch & lomb americas inc. - fluorescein sodium (unii: 93x55pe38x) (fluorescein - unii:tpy09g7xir), benoxinate hydrochloride (unii: 0ve4u49k15) (benoxinate - unii:axq0jym303) - fluorescein sodium and benoxinate hydrochloride ophthalmic solution, 0.3%/0.4% is indicated for ophthalmic procedures in adult and pediatric patients requiring a disclosing agent in combination with a topical ophthalmic anesthetic agent. fluorescein sodium and benoxinate hydrochloride ophthalmic solution, 0.3%/0.4% is contraindicated in patients with known hypersensitivity to any component of this product. risk summary there are no available data on the use of fluorescein sodium and benoxinate hydrochloride ophthalmic solution, 0.3%/0.4% in pregnant women to inform any drug associated risk. adequate animal reproduction studies have not been conducted with fluorescein sodium and/or benoxinate hydrochloride. fluorescein sodium and benoxinate hydrochloride ophthalmic solution, 0.3%/0.4% should be given to a pregnant woman only if clearly needed. risk summary there are no data on the presence of fluorescein sodium or benoxinate hydrochloride in human milk after ocular administration of fluorescein sodium and beno

United States - English - NLM (National Library of Medicine)

ocusoft, inc. - fluorescein sodium (unii: 93x55pe38x) (fluorescein - unii:tpy09g7xir), benoxinate hydrochloride (unii: 0ve4u49k15) (benoxinate - unii:axq0jym303) - flourescein sodium and benoxinate hydrochloride opthalmic solution usp, 0.25%/0.4% is a disclosing agent with rapid anesthetic action of short duration. fluorescein sodium is represented by the following structural formula: chemical name: spiro  [isobenzofuran-1  (3h ),9'-[9h ]  xanthene]-3-one,  3',6'  dihydroxy, disodium salt. benoxinate hydrochloride is represented by the following structural formula: chemical name: 2-(diethylamino) ethyl 4-amino-3butoxybenzoate monohydrochloride. for procedures requiring a disclosing agent in combination with a topical ophthalmic anesthetic agent such as tonometry, gonioscopy, removal of corneal foreign bodies and other short corneal or conjunctival procedures. known hypersensitivity to any component of this product.

United States - English - NLM (National Library of Medicine)

altaire pharmaceuticals inc. - fluorescein sodium (unii: 93x55pe38x) (fluorescein - unii:tpy09g7xir), benoxinate hydrochloride (unii: 0ve4u49k15) (benoxinate - unii:axq0jym303) - altafluor benox (fluorescein sodium and benoxinate hydrochloride ophthalmic solution) 0.25%/0.4% is indicated for ophthalmic procedures requiring a disclosing agent in combination with a topical ophthalmic anesthetic agent. altafluor benox is contraindicated in patients with known hypersensitivity to any component of this product. risk summary   there are no available data on the use of altafluor benox in pregnant women to inform any drug associated risk. adequate animal reproduction studies have not been conducted with fluorescein sodium and/or benoxinate hydrochloride. altafluor benox should be given to a pregnant woman only if clearly needed. risk summary    there are no data on the presence of fluorescein sodium or benoxinate hydrochloride in human milk after ocular administration of altafluor benox, the effects on the breastfed infant, or the effects on milk production. the developmental and health benefits of breastfeeding should be considered, along with the mother’s clinical need for altafluor benox a

Canada - English - Health Canada

chauvin pharmaceuticals limited - benoxinate hydrochloride - drops - .4% - benoxinate hydrochloride .4% - local anesthetics

United States - English - NLM (National Library of Medicine)

akorn, inc. - fluorescein sodium (unii: 93x55pe38x) (fluorescein - unii:tpy09g7xir), benoxinate hydrochloride (unii: 0ve4u49k15) (benoxinate - unii:axq0jym303) - for procedures requiring a disclosing agent in combination with an anesthetic agent such as tonometry, gonioscopy, removal of corneal foreign bodies and other short corneal or conjunctival procedures. known hypersensitivity to any component of this product.

Canada - English - Health Canada

bausch & lomb inc - fluorescein sodium; benoxinate hydrochloride - solution - 0.25%; 0.4% - fluorescein sodium 0.25%; benoxinate hydrochloride 0.4% - local anesthetics